PRME241220C7500
- 0.00
- 0.000.00%
Prime Medicine Newsroom
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating, Maintains Target Price $5
Prime Medicine, Inc. (PRME) Gets a Hold From Morgan Stanley
A Quick Look at Today's Ratings for Prime Medicine(PRME.US), With a Forecast Between $7 to $14
Prime Medicine Is Maintained at Buy by Chardan Capital
Stifel Nicolaus Sticks to Its Hold Rating for Prime Medicine, Inc. (PRME)
Prime Medicine Analyst Ratings
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
Prime Medicine, Inc. Receives Buy Rating From Arthur He CFA: Strategic Partnerships and Pipeline Focus Drive Promising Future Prospects
TD Cowen Maintains Prime Medicine(PRME.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Nuvalent (NUVL)
Prime Medicine, Inc. (PRME) Receives a Buy From TD Cowen
BMO Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $19
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $14
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
Prime Medicine Analyst Ratings
Prime Medicine's Promising Gene Editing Advancements Justify Buy Rating
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating, Cuts Target Price to $5
BMO Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $19
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.